Ramírez-Rentería C, López-Juárez N, González-Virla B

Language: Spanish
References: 11
Page: 30-33
PDF size: 73.51 Kb.

ABSTRACT

Well-differentiated thyroid carcinoma (WTC) constitutes 1% of all types of cancer and it is the most common endocrine neoplasm. Treatment with thyroidectomy and radioactive iodine allows for excellent long-term survival rates but patients sometimes develop secondary tumors. The development of multiple myeloma in WTC survivors has been previously described but a causal relationship between the two conditions has yet to be established. We here in present the case of an 83 year-old woman who was diagnosed with multiple myeloma 10 years after being in remission from a papillary thyroid carcinoma.

REFERENCES

1. Rubino C, de Vathaire M, Dottorini ME, Hall P, Shvartz C, Covette JE, Dondon MG, Abbas MT, Langlois C, Schlumberger M. Second primary malignancies in thyroid cancer patients. Br J Cancer 2003; 89: 1638-1644.

2. Sandeep TC, Strachan MW, Reynolds RM, Brewster DH, Scélo G, Pukkala E, Hemminki K, Anderson A, Tracey E, Friis S, McBride ML, Kee-Seng C, Pompe-Kirn V, Kliewer EV, Tonita JM, Jonasson JG, Martos C, Boffetta P, Brennan P. Second primary cancers in thyroid cancer patients: A multinational record linkage study. J Clin Endocrinol Metab 2005; 90: 1819-1829.

3. Omür O, Ozcan Z, Yacizi C, Akgün A, Oral A, Ozkiliç H. Multiple primary tumors in differentiated thyroid carcinoma and relationship to thyroid cancer outcome. Endocr J 2008; 55: 365-372.

4. Eustatia-Rutten CF, Corssmit EP, Biermasz NR, Pereira AM, Romijn JA, Smit JW. Survival and death causes in differentiated thyroid carcinoma. J Clin Endocrinol Metab 2006; 91: 313-319.

5. Canchola AJ, Horn-Ross PL, Purdie DM. Risk of second primary malignancies in women with papillary thyroid cancer. Am J Epidemiol 2006; 163: 521-527.

6. Verkooijen RB, Smit JW, Romjin JA, Stokkel MP. The incidence of second primary tumors in thyroid cancer patients is increased, but not related to treatment of thyroid cancer. Eur J Endocrinol 2006; 155: 801-806.

7. Lin CS, Ho CL. Light chain myeloma in a patient with thyroid carcinoma. Ann Hematol 2008; 87: 163-164.

8. Rebbaa A, Chu F, Davis FB, Davis PJ, Mousa SA. Novel function of the thyroid hormone analog tetraiodothyroacetic acid: a cancer chemosensitizing and anti-cancer agent. Angiogenesis 2008; 11: 269-276.

9. Nau KC, Lewis WD. Multiple myeloma: diagnosis and treatment. Am Fam Physician 2008; 78: 853-859.

10. Kyle RA. Diagnosis and treatment of multiple myeloma in 2010. Hematologia 2010; 11: 30-39.

11. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Bladé J, Boccadoro M, Child JA, Avet-Loiseau H, Kyle RA, Lahuerta JJ, Ludwig H, Morgan G, Powles R, Shimizu K, Shustik C, Sonneveld P, Tosi P, Turesson I, Westin J. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412-3420.